NCT05651672招募中2 期
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations That Failed Standard Therapy
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年12月2日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Overall response rate (ORR)
研究概览
简要总结
This study is a prospective single-arm phase II study to evaluate the efficacy and safety of Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed standard therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 or older
- •Histologically or cytologically confirmed unresectable advanced, recurrent or metastatic gastrointestinal cancer
- •Have at least one measurable lesion according to RECIST v1.1
- •With histologically confirmed FGFR1-3 alterations, including but not limited to amplification, mutation, fusion/rearrangement
- •Disease progression after prior standard therapy
- •No previous use of small molecule multi-target inhibitors targeting the FGFR pathway (including but not limited to anlotinib, lenvatinib, sorafenib, apatinib)
- •ECOG performance status of 0~1
- •Expected survival time > 3 months
- •Sufficient organ functions
- •Negative pregnancy test results of childbearing age women
- •Patients at risk of conception (including their partners) need to use contraception
排除标准
- •Diagnosed with malignant tumors other than gastrointestinal cancer within 5 years before the first dose, excluding radically cured cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/or radically resected carcinoma in situ
- •Prior receipt of selective FGFR inhibitors
- •Have received any other investigational drug or participated in another interventional clinical trial within 28 days before the first dose, or have received anti-tumor drug treatment within 28 days before the first dose (including Chinese herbal medicine with anti-tumor indications)
- •Have not recovered ( ≤ grade 1 or reaching the baseline, excluding asthenia and alopecia) from toxicity and/or complications caused by any intervention before the start of treatment
- •Known symptomatic central nervous system metastasis and/or carcinomatous meningitis.
- •Known history of allotransplantation or allogeneic hematopoietic stem cell transplantation
- •Abnormal laboratory parameters listed below:
- •Serum phosphate > upper limit of normal (ULN)
- •Serum calcium exceeds the normal range, or the calcium concentration corrected for serum albumin exceeds the normal range when serum albumin exceeds the normal range
- •Potassium level < lower limit of normal (LLN)#potassium levels can be corrected by supplements at screening
- •Known history of human immunodeficiency virus (HIV) infection or confirmed with positive immune test results
- •Presence of severe infection in the active phase or with poor clinical control
- •Pleural effusion, ascites, or pericardial effusion with obvious clinical symptoms that require drainage
- •Acute or chronic active hepatitis B or C infection
- •Clinically significant or uncontrolled heart diseases, including unstable angina, acute myocardial infarction within 6 months before the first dose, grade III/IV congestive heart failure (New York Heart Association), and uncontrolled arrhythmia (patients with pacemakers or with atrial fibrillation but well controlled heart rate are allowed)
- •ECG changes or medical history considered clinically significant by the investigator, QTcF interval > 480 ms at screening, JTc interval can be used instead of QTc interval (in such cases, JTc must be ≤ 340 ms) for patients with intraventricular conduction block (QRS interval > 120 ms)
- •Uncontrolled hypertension (systolic pressure > 160 mmHg or diastolic pressure > 100 mmHg) after the optimal medical treatment, or a history of hypertensive crisis or hypertensive encephalopathy
- •Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis with Child-Pugh grade B or C
- •Have received a major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose, or will receive a major surgery during the study treatment period
- •Not fully recovered from toxicity and/or complications of a major surgery before the study treatment
- •Pregnant or lactating women, or patients expected to conceive or give birth during the study period from the screening to the completion of the safety follow-up visit (90 days after the last dose for male subjects)
- •Have received radiotherapy within 4 weeks before the first dose.
- •History of disorders of calcium and phosphorus metabolism or systemic electrolyte metabolism imbalance with ectopic calcification of soft tissues (excluding calcification of soft tissues such as skin, kidneys, tendon, or blood vessels without systemic electrolyte metabolism imbalance caused by injury, disease, and old age)
- •Clinically significant corneal or retinal diseases confirmed by ophthalmological examination
- •Prior receipt of any potent CYP3A4 inhibitor or inducer within 14 days or 5 half lives (whichever is shorter) before the first dose. Ketoconazole is allowed for external use
- •Known allergic reactions to pemigatinib or excipients of pemigatinib
- •Unable or unwilling to swallow pemigatinib or are suffering from significant digestive system diseases that may interfere with absorption, metabolism, or excretion
研究组 & 干预措施
experimental group
Experimental
Pemigatinib
干预措施: Pemigatinib (Drug)
结局指标
主要结局
Overall response rate (ORR)
时间窗: up to 2 years
Defined as proportion of patients who have a best response of complete response (CR) + partial response (PR) according to the RECIST 1.1 criteria
次要结局
- Overall Survival (OS)(Up to 4 years)
- Duration of Response (DOR)(up to 4 years)
- Adverse Events (AEs)(Up to 2 years)
- Progress Free Survival (PFS)(Up to 4 years)
- Disease Control Rate (DCR)(Up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical SurgeryUrothelial CancerNCT04294277European Association of Urology Research Foundation2
招募中
2 期
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard TherapyAdvanced Non-Small Cell Lung CancerNCT05287386The First Affiliated Hospital of Xiamen University20
已完成
2 期
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 RearrangementCholangiocarcinomaNCT04256980Innovent Biologics (Suzhou) Co. Ltd.34
尚未招募
2 期
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal CancerLocally Advanced Rectal CancerNCT06760520The First Affiliated Hospital of Zhengzhou University40
尚未招募
2 期
IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)Esophageal Squamous Cell Carcinoma (ESCC)PD-1 InhibitorsNCT06078657The First Affiliated Hospital of Zhengzhou University46